Possible benefits of low molecular weight heparins. 1994

L Breimer

UI MeSH Term Description Entries
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015201 Meta-Analysis as Topic A quantitative method of combining the results of independent studies (usually drawn from the published literature) and synthesizing summaries and conclusions which may be used to evaluate therapeutic effectiveness, plan new studies, etc., with application chiefly in the areas of research and medicine. Clinical Trial Overviews,Data Pooling,Overviews, Clinical Trial,Clinical Trial Overview,Data Poolings,Meta Analysis as Topic,Overview, Clinical Trial

Related Publications

L Breimer
September 1994, Current opinion in cardiology,
L Breimer
January 1990, Medicina (Florence, Italy),
L Breimer
September 1997, The New England journal of medicine,
L Breimer
December 1998, Hematology/oncology clinics of North America,
L Breimer
December 1993, Presse medicale (Paris, France : 1983),
L Breimer
January 1986, Pathologie-biologie,
L Breimer
April 1993, Medicina clinica,
L Breimer
April 1998, Der Internist,
L Breimer
January 1989, Annales pharmaceutiques francaises,
L Breimer
August 1996, Journal of internal medicine,
Copied contents to your clipboard!